AbbVie Inc. - Form 8.1 - Statement of Stock Purchase by Director
NORTH CHICAGO, Ill., Jan. 9, 2020 /PRNewswire/ -- AbbVie issued the following forms today.
IRISH TAKEOVER PANEL |
DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013 |
DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS |
1. KEY INFORMATION | |
Name of person dealing (Note 1) | Edward Rapp |
Company dealt in | AbbVie Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | Common shares, par value $0.01 per share |
Date of dealing | 31 December 2019 |
2. INTERESTS AND SHORT POSITIONS | ||||||
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) | ||||||
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 30,662 (0.002%) | |||||
(2) Derivatives (other than options) | 16,872 (0.001%) | |||||
(3) Options and agreements to purchase/sell | N/A | |||||
Total | 47,534 (0.003%) | |||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A | ||||||
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
3. DEALINGS (Note 4) | ||
(a) Purchases and sales | ||
Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
(b) Derivatives transactions (other than options transactions) | |||
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit (Note 5) |
Stock equivalent unit | Director fee credit to stock equivalent unit account | 384 | $88.54 |
(c) Options transactions in respect of existing relevant securities | ||||||
(i) Writing, selling, purchasing or varying | ||||||
Product name, e.g. call option | Writing, selling, | Number of securities | Exercise | Type, e.g. | Expiry | Option money |
(ii) Exercising | ||
Product name, e.g. call option | Number of securities | Exercise price |
(d) Other dealings (including transactions in respect of new securities) (Note 4) | ||
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
4. OTHER INFORMATION |
Agreements, arrangements or understandings relating to options or derivatives |
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
Is a Supplemental Form 8 attached? (Note 9) | YES/NO√ |
Date of disclosure | 8 January 2020 |
Contact name | Steven L. Scrogham |
Telephone number | 847-938-6166 |
Name of offeree/offeror with which acting in concert | AbbVie Inc. |
Specify category and nature of acting in concert status | Director of AbbVie Inc. |
1. KEY INFORMATION | |
Name of person dealing (Note 1) | Edward Liddy |
Company dealt in | AbbVie Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | Common shares, par value $0.01 per share |
Date of dealing | 31 December 2019 |
2. INTERESTS AND SHORT POSITIONS | ||||||
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) | ||||||
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 22,669 (0.002%) | |||||
(2) Derivatives (other than options) | 24,692 (0.002%) | |||||
(3) Options and agreements to purchase/sell | N/A | |||||
Total | 47,361 (0.003%) | |||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A | ||||||
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
3. DEALINGS (Note 4) | ||
(a) Purchases and sales | ||
Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
(b) Derivatives transactions (other than options transactions) | |||
Product name, | Nature of transaction | Number of relevant securities | Price per unit |
Stock equivalent unit | Director fee credit to stock equivalent unit account | 367 | $88.54 |
(c) Options transactions in respect of existing relevant securities | ||||||
(i) Writing, selling, purchasing or varying | ||||||
Product name, e.g. call option | Writing, selling, | Number of securities | Exercise | Type, e.g. American, | Expiry | Option money |
(ii) Exercising | ||
Product name, e.g. call option | Number of securities | Exercise price per |
(d) Other dealings (including transactions in respect of new securities) (Note 4) | ||
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
4. OTHER INFORMATION |
Agreements, arrangements or understandings relating to options or derivatives |
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
Is a Supplemental Form 8 attached? (Note 9) | YES/NO√ |
Date of disclosure | 8 January 2020 |
Contact name | Steven L. Scrogham |
Telephone number | 847-938-6166 |
Name of offeree/offeror with which acting in concert | AbbVie Inc. |
Specify category and nature of acting in concert status | Director of AbbVie Inc. |
1. KEY INFORMATION | |
Name of person dealing (Note 1) | Robert Alpern |
Company dealt in | AbbVie Inc. |
Class of relevant security to which the dealings being disclosed relate (Note 2) | Common shares, par value $0.01 per share |
Date of dealing | 31 December 2020 |
2. INTERESTS AND SHORT POSITIONS | ||||||
(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3) | ||||||
Long | Short | |||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | 26,107 (0.002%) | |||||
(2) Derivatives (other than options) | 6,933 (0.000%) | |||||
(3) Options and agreements to purchase/sell | N/A | |||||
Total | 33,040 (0.002%) | |||||
(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3) N/A | ||||||
Class of relevant security: | Long | Short | ||||
Number | (%) | Number | (%) | |||
(1) Relevant securities | ||||||
(2) Derivatives (other than options) | ||||||
(3) Options and agreements to purchase/sell | ||||||
Total | ||||||
3. DEALINGS (Note 4) | ||
(a) Purchases and sales | ||
Purchase/sale | Number of relevant securities | Price per unit (Note 5) |
(b) Derivatives transactions (other than options transactions) | |||
Product name, e.g. CFD | Nature of transaction (Note 6) | Number of relevant securities (Note 7) | Price per unit |
Stock equivalent unit | Director fee credit to stock equivalent unit account | 77 | $88.54 |
(c) Options transactions in respect of existing relevant securities | ||||||
(i) Writing, selling, purchasing or varying | ||||||
Product name, e.g. call option | Writing, selling, | Number of securities | Exercise | Type, e.g. American, European etc.
| Expiry | Option money |
(ii) Exercising | ||
Product name, e.g. call option | Number of securities | Exercise price per |
(d) Other dealings (including transactions in respect of new securities) (Note 4) | ||
Nature of transaction (Note 8) | Details | Price per unit (if applicable) (Note 5) |
4. OTHER INFORMATION |
Agreements, arrangements or understandings relating to options or derivatives |
Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated. |
Is a Supplemental Form 8 attached? (Note 9) | YES/NO√ |
Date of disclosure | 8 January 2020 |
Contact name | Steven L. Scrogham |
Telephone number | 847-938-6166 |
Name of offeree/offeror with which acting in concert | AbbVie Inc. |
Specify category and nature of acting in concert status | Director of AbbVie Inc. |
View original content:http://www.prnewswire.com/news-releases/abbvie-inc---form-8-1---statement-of-stock-purchase-by-director-300984678.html
SOURCE AbbVie
Editor Details
-
Company:
- PR Newswire
- Website:
